FDA Vulnerable To Meddling In Climate Of Distrust – Commish Hamburg
This article was originally published in The Rose Sheet
An atmosphere of distrust in government makes FDA vulnerable to congressional meddling, Commissioner Margaret Hamburg suggested in a July 25 presentation to consumer group Public Citizen.
You may also be interested in...
FDA is considering further “modulations” of its current approaches to drug approvals in order to encourage innovation and get products to market more quickly, Commissioner Margaret Hamburg commented during a panel session at the Biotechnology Industry Organization International Convention in Washington, D.C. on June 28.
The House passes a fiscal 2012 appropriations bill with significant cuts to a program that provides infant formula for low-income women.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.